Bayer Healthcare LLC

Gladiator Biosciences, Inc.

Coagulant Therapeutics Corporation

R.p.scherer Technologies, Inc.

Bayer Intellectual Property Gmbh

Maxine Bauzon

Terry Hermiston

David Rabuka

Christopher H Contag

Robyn M Barfield

Penelope M Drake

Richard N Harkins

Yun Cheol Kim

Peter Kretschmer

Ayodele O Ogunkoya

Fang Jin

Masamitsu Kanada

Jonathan Hardy

Peter Droescher

Paul Szymanski

Konstantin Levitsky

A method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method are described herein.

Method of targeting exosomes

The present disclosure provides antibodies specific for Mucin 1. Nucleic acids that encode one or both of the variable chains of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are also useful in various diagnostic, and monitoring applications, which are also provided.

Antibody specific for Mucin-1 and methods of use thereof

Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.

Short-acting Factor VII polypeptides

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.

GLA domains as therapeutic agents

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.

Gla domains as targeting agents

Short-acting factor VII polypeptides

The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consisting of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.

Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells

Growing community of inventors

Hercules, CA, United States of America

Maxine Bauzon